Asparaginase in the management of adult acute lymphoblastic leukaemia: Is it used appropriately?

Cancer Treatment Reviews

Volumn 37, Issue 3, 2011, Pages 202-207

  Patil, Sushrut ^a,b   Coutsouvelis, John ^a,b   Spencer, Andrew ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Acute lymphoblastic leukaemia; Asparaginase; Asparagine; L asparaginase; Leukaemia

Indexed keywords

ASPARAGINASE; DOXORUBICIN; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ADULT DISEASE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CEREBROVASCULAR ACCIDENT; CHILDHOOD CANCER; COMA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOLERANCE; DRUG USE; HEADACHE; HUMAN; LETHARGY; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMNOLENCE; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; CLINICAL TRIALS AS TOPIC; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 79952006939     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.08.002     Document Type: Review

References (45)

1. Clementi A. Desamidation enzymatique de l'asparagine. Arch Internat Physiol 1922, 19:369.
2. Kidd J.G. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum - course of transplanted cancers of various kinds in mice and rats given guinea pig serum or rabbit serum. J Exp Med 1953, 98:565-582.
3. Broome J.D. Evidence that the l-asparaginase of guinea pig serum is responsible for its anti-lymphoma effects. J Exp Med 1963, 118:99-120.
4. Oettgen H.F., Old L.J., Boyse E.A. Inhibition of leukemias in man by l-asparaginase. Cancer Res 1967, 27:2619-2631.
5. Hill J.M., Roberts J., Loeb E. l-asparaginase therapy for leukemia and other malignant neoplasms. J Am Med Assoc 1967, 202:882-888.
6. Ohnuma T., Holland J.F., Nagal G. Effects of l-asparaginase in acute myelocytic leukemia. J Am Med Assoc 1969, 210:1919-1921.
7. Caruso V., Lacoviello L., Di Castelnuovo A. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006, 108:2216-2222.
8. Payne J.H., Vora A.J. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol 2007, 138:430-445.
9. Asselin B.L., Ryan D., Frantz C.N., et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by l-asparaginase. Cancer Res 1989, 49:4363-4368.
10. Aslanian A.M., Kilberg M.S. Multiple adaptive mechanisms affect asparagine synthase substrate availability in asparaginase-resistant MOLT-4 leukemia cells. Biochem J 2001, 358:59-67.
11. Appel I.M., den Boer M., Meijerink J.P.P., Veerman A.J., Reniers N.C., Pieters R. Up-regulation of asparagine synthetase expression is not linked to the clinical response to l-asparaginase in pediatric acute lymphoblastic leukemia. Blood 2006, 107:4244-4249.
12. Duval M., Suciu S., Ferster A., et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of randomized European Organisation for Research and Treatment of Cancer - Children's Leukemia Group phase 3 trial. Blood 2002, 99:2734-2739.
13. Asselin B.L., Whitin J.C., Coppola D.J., et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993, 11:1780-1786.
14. Woo M., Hak L., Storm M., et al. Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. J Clin Oncol 1999, 17:1568-1573.
15. Dibenedetto S., Cataldo A., Ragusa R., Meli C., Nigro L. Levels of l-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia. J Clin Oncol 1995, 13:339-344.
16. Smith M., Arthur C., Camitta B., et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996, 14:18-24.
17. Weiss M.A., Lamanna N. In adult ALL, less is now more. Blood 2006, 107:852-853.
18. Pui C.H., Evans W.E. Treatment of acute lymphoblastic leukemia. N Eng J Med 2006, 354:166-178.
19. Stock W., La M., Sanford B., et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of children's cancer group and cancer and leukemia group b studies. Blood 2008, 112:1646-1654.
20. Huguet F., Raffoux E., Thomas X., et al. Pediatric-inspired therapy in adults with Philadelphia-chromosome negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009, 27(6):911-918.
21. Storring J.M., Brandwein J., Gupta V., et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukemia (ALL) with a modified Paediatric Regimen. Br J Haematol 2009, 146:76-85.
22. Kantarjian H., Thomas D., O'Brien S., et al. Long-term follow up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (Hyper-CVAD), a dose intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004, 101:2788-2801.
23. Thomas X., Boiron J.M., Huguet F., et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004, 22:4075-4086.
24. Jones B., Holland J.F., Glidewell O., et al. Optimal use of l-asparaginase (NSC-109229) in acute lymphocytic leukemia. Med Pediatr Oncol 1977, 3:387-400.
25. Sallan S.E., Hitchcock-Bryan S., Gelber R., et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983, 43:5601-5607.
26. Silverman L.B., Gelber R.D., Dalton V.K., et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001, 97:1211-1218.
27. Avramis V.I., Sencer S., Periclou A.P., et al. A randomised comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002, 99:1986-1994.
28. Abshire T., Pollock B., Billett A., Bradley P., Buchanan G. Weekly polyethylene glycol conjugated l-asparaginase compared to biweekly dosing production superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study. Blood 2000, 96:1709-1715.
29. Durrant I.J., Prentice H.G., Richards S.M. Intensification of treatment for adults with acute lymphoblastic leukaemia: results of U.K. Medical Research Council randomized trial UKALL XA. Br J Haematol 1997, 99:84-92.
30. Goldstone A.H., Richards S.M., Lazarus H.M., et al. In adults with standard risk acute lymphoblastic leukaemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: the final results of the international ALL trial (MRC UKALLXII/ECOG E2993). Blood 2008, 111:1827-1833.
31. Larson R.A., Dodge R.K., Burns C.P., et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 1995, 85:2025-2037.
32. Gottlieb A.J., Weinberg V., Ellison R.R., et al. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by Cancer and Leukemia Group B. Blood 1984, 64:267-274.
33. Wetzler M., Sanford B., Kurtzberg J. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukaemia: Cancer and Leukemia Group B Study 9511. Blood 2007, 109:4164-4169.
34. Elliott M., Wolf R., Hook C., Pruthi R., Heit J., Letendre L. Thromboembolism in adults with acute lymphoblastic leukemia during induction with l-asparaginase containing multi-agent regimens: Incidence, risk factors and possible role of antithrombin. Leuk Lymph 2004, 45:1545-1551.
35. Parma M., Belotti D., Pogliani E. Management of l-asparaginase induced prothrombotic state in acute lymphoblastic leukemia. Haematologica 1996, 81:191.
36. Douer D., Yampolsky H., Cohen L., et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukaemia. Blood 2007, 109:2744-2750.
37. Boos J., Werber G., Ahilke E., et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996, 32A:1544-1550.
38. Avramis V.I., Holcenberg J.S., Ettinger A.G., Stork L.C., La M., Gaynon P.S. Failure of asparagine (ASN) depletion, not inadequate asparaginase (ASNase) activity, predicts relapse in standard risk (SR) childhood acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) report. Blood 2007, 110. [abstract 588].
39. Ahlke E., Nowak-Gottl U., Schulze-Westhoff P., et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Hematol 1997, 96:675-681.
40. Oettgen H., Stephenson P., Schwartz M. Toxicity of E. coli asparaginase in man. Cancer 1970, 15:253-278.
41. Killander D., Dohlwitz A., Engstedt L., et al. Hypersensitivity reactions and antibody formation during l-asparaginase treatment of children and adults with acute leukemia. Cancer 1976, 37:220-228.
42. Albertsen B., Schroder H., Jakobsen P., et al. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol 2002, 38:310-316.
43. Panosyan E., Seibel N., Martin-Aragon S., et al. Asparaginase antibody and asparaginase activity in children with high-risk acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2004, 26:217-226.
44. Wang B., Relling M., Storm M., et al. Evaluation of immunological cross reaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 2003, 17:1583-1588.
45. Zalewska-Szewczyk B., Anderzejewski W., Mlynarski W., Jedrychowska-Danska K., Witas H., Bodalski J. The anti-asparaginase antibodies correlate with l-asparaginase activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymph 2007, 48(5):931-936.